Cocrystal Pharma Inc

-0.02 (-4.11%)
Products, Other Pre-Announcement

Cocrystal Pharma Receives FDA Guidance To Advance Clinical Development Of Its COVID-19 Antiviral CDI-45205

Published: 01/06/2022 13:29 GMT
Cocrystal Pharma Inc (COCP) - Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of Its Covid-19 Antiviral Cdi-45205.
Response to Pre-ind Briefing Package Supports Pathway to Initiating a Phase 1 Clinical Study in 2022.
Cocrystal Pharma - Have Clearer Pathway for Planned Phase 1 Single-ascending-dose & Multiple-ascending-dose Study That Co Expects to Initiate in 2022.
Intends to Conduct Cdi-45205 Formulation Development, Ind-enabling Studies and Virology Assessments.
In Second Covid-19 Program, Plans to Begin a Phase 1 Study Also in 2022 With an Orally Administered Main Protease Inhibitor.